Oncolytic viruses are a relatively new class of anti-cancer immunotherapy agents. Several viruses have undergone evaluation in clinical trials in the last decades, and the first agent is about to be approved to be used as a novel cancer therapy modality. In the current review, an overview is presented on recent (pre)clinical developments in the field of oncolytic viruses that have previously been or currently are being evaluated in clinical trials. Special attention is given to possible safety issues like toxicity, environmental shedding, mutation and reversion to wildtype virus.

, , , , , , ,
doi.org/10.1080/21645515.2015.1037058, hdl.handle.net/1765/90937
Human Vaccines and Immunotherapeutics
Department of Gastroenterology & Hepatology

Buijs, P., Verhagen, J. H. E., van Eijck, C., & van den Hoogen, B. (2015). Oncolytic viruses: From bench to bedside with a focus on safety. Human Vaccines and Immunotherapeutics (Vol. 11, pp. 1573–1584). doi:10.1080/21645515.2015.1037058